Leukocyte Adhesion Defect - Type I
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Rocket PharmaceuticalsNEW YORK, NY
2 programs1
1
RP-L201Phase 1/21 trial
RP-L201Phase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Rocket PharmaceuticalsRP-L201
Rocket PharmaceuticalsRP-L201
Clinical Trials (2)
Total enrollment: 9 patients across 2 trials
A Clinical Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Start: Aug 2019Est. completion: Sep 20239 patients
Phase 1/2Completed
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I
Start: Apr 2019Est. completion: Oct 20210
Phase 1Withdrawn
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space